Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: Female

Summary

This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Khorana score = 1

• Over age 18

• English-speaking female patients

• Able to consent

• Receiving neoadjuvant chemotherapy Cancer of primary ovarian, fallopian tube, mullerian, or peritoneal origin

Exclusion Criteria:

• Allergy or intolerance to study medication

• Indication for a non-aspirin form of antiplatelet (i.e. cardiac stent)

• Already on alternative form of anticoagulation

• Active bleeding

• High risk for active bleeding (i.e. recent intracranial bleed or gastrointestinal bleed, known brain metastases)

• Thrombocytopenia (platelets <50,000)

• Unable to complete medication adherence diary

• Unable to take oral medications